Stifel's Positive Outlook on Rapport Therapeutics' Drug Candidate RAP-219
Tuesday, 2 July 2024, 18:45
![Seeking Alpha](https://store.livarava.com/ce4e4c81-38c4-11ef-bf77-91148d8070a3.jpg)
Stifel Initiates Coverage on Rapport Therapeutics
Stifel has recently initiated coverage of Rapport Therapeutics with a buy rating, signaling optimism regarding the company's performance.
RAP-219: Lead Drug Candidate
RAP-219 holds significant promise in the treatment of epilepsy, attracting attention for its potential efficacy and market impact.
Rapport Therapeutics is strategically positioned to leverage the growing demand for innovative epilepsy treatments, with RAP-219 leading the way.
Do you want to advertise here? Contact us